NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events

NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events
Item 8.01.Other Events.

Story continues below

On September 7, 2017, NewLink Genetics Corporation, a Delaware corporation, or the Company, issued a press release titled "Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma."

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Section9 – Financial Statements and Exhibits

Item 9.01.FinancialStatements and Exhibits.

(d) Exhibits.

ExhibitNumber

Description

99.1

Press Release, dated September 7, 2017, entitled “Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma”


NEWLINK GENETICS CORP Exhibit
EX-99.1 2 nlnk-20170907x8kxex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced MelanomaPivotal Trial of Indoximod in Advanced Melanoma to Include Both PD-1 Inhibitors,…
To view the full exhibit click here

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

An ad to help with our costs